|
1
|
Massague J: G1 cell-cycle control and
cancer. Nature. 432:298–306. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sherr CJ: Mammalian G1 cyclins. Cell.
73:1059–1065. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dowdy SF, Hinds PW, Louie K, Reed SI,
Arnold A and Weinberg RA: Physical interaction of the
retinoblastoma protein with human D cyclins. Cell. 73:499–511.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xiong Y, Hannon GJ, Zhang H, Casso D,
Kobayashi R and Beach D: p21 is a universal inhibitor of cyclin
kinases. Nature. 366:701–704. 1993. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sherr CJ and Roberts JM: CDK inhibitors:
positive and negative regulators of G1-phase progression. Genes
Dev. 13:1501–1512. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Roussel MF: The INK4 family of cell cycle
inhibitors in cancer. Oncogene. 18:5311–5317. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Burkhart DL and Sage J: Cellular
mechanisms of tumour suppression by the retinoblastoma gene. Nat
Rev Cancer. 8:671–682. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kelloff GJ, Crowell JA, Hawk ET, Steele
VE, Lubet RA, Boone CW, Covey JM, Doody LA, Omenn GS, Greenwald P,
Hong WK, Parkinson DR, Bagheri D, Baxter GT, Blunden M, Doeltz MK,
Eisenhauer KM, Johnson K, Knapp GG, Longfellow DG, Malone WF,
Nayfield SG, Seifried HE, Swall LM and Sigman CC: New agents for
cancer chemoprevention. J Cellular Biochem (Suppl). 26:1–28. 1996.
View Article : Google Scholar
|
|
9
|
Crowell PL: Prevention and therapy of
cancer by dietary monoterpenes. J Nutr. 129:S775–S778.
1999.PubMed/NCBI
|
|
10
|
Stark MJ, Burke YD, McKinzie JH, Ayoubi AS
and Crowell PL: Chemotherapy of pancreatic cancer with the
monoterpene perillyl alcohol. Cancer Lett. 96:15–21. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shi W and Gould MN: Induction of
differentiation in neuro-2A cells by the monoterpene perillyl
alcohol. Cancer Lett. 95:1–6. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mills JJ, Chari RS, Boyer IJ, Gould MN and
Jirtle RL: Induction of apoptosis in liver tumors by the
monoterpene perillyl alcohol. Cancer Res. 55:979–983.
1995.PubMed/NCBI
|
|
13
|
Wagner JE, Huff JL, Rust WL, Kingsley K
and Plopper GE: Perillyl alcohol inhibits breast cell migration
without affecting cell adhesion. J Biomed Biotechnol. 2:136–140.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Loutrari H, Hatziapostolou M, Skouridou V,
Papadimitriou E, Roussos C, Kolisis FN and Papapetropoulos A:
Perillyl alcohol is an angiogenesis inhibitor. J Pharmacol Exp
Ther. 311:568–575. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shi W and Gould MN: Induction of
cytostasis in mammary carcinoma cells treated with the anticancer
agent perillyl alcohol. Carcinogenesis. 23:131–142. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wiseman DA, Werner SR and Crowell PL: Cell
cycle arrest by the isoprenoids perillyl alcohol, geraniol, and
farnesol is mediated by p21Cip1 and p27Kip1
in human pancreatic adenocarcinoma cells. J Pharmacol Exp Ther.
320:1163–1170. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Haag JD and Gould MN: Mammary carcinoma
regression induced by perillyl alcohol, a hydroxylated analog of
limonene. Cancer Chemother Pharmacol. 34:477–483. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu G, Oettel K, Bailey H, Ummersen LV,
Tutsch K, Staab MJ, Horvath D, Alberti D, Arzoomanian R, Rezazadeh
H, McGovern J, Robinson E, DeMets D and Wilding G: Phase II trial
of perillyl alcohol (NSC 641066) administered daily in patients
with metastatic androgen-independent prostate cancer. Invest New
Drugs. 21:367–372. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bailey HH, Attia S, Love RR, Fass T,
Chappell R, Tutsch K, Harris L, Jumonville A, Hansen R, Shapiro GR
and Stewart JA: Phase II trial of daily oral perillyl alcohol (NSC
641066) in treatment-refractory metastatic breast cancer. Cancer
Chemother Pharmacol. 62:149–157. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
da Fonseca CO, Simão M, Lins IR, Caetano
RO, Futuro D and Quirico-Santos T: Efficacy of monoterpene perillyl
alcohol upon the survival rate of patients with recurrent
glioblastoma. J Cancer Res Clin Oncol. 137:287–293. 2011.PubMed/NCBI
|
|
21
|
Koyama M, Izutani Y, Goda AE, Matsui TA,
Horinaka M, Tomosugi M, Fujiwara J, Nakamura Y, Wakada M, Yogosawa
S, Sowa Y and Sakai T: Histone deacetylase inhibitors and
15-deoxy-Delta12,14-prostaglandin J2 synergistically
induce apoptosis. Clin Cancer Res. 16:2320–2332. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hitomi T, Matsuzaki Y, Yokota T, Takaoka Y
and Sakai T: p15INK4b in HDAC inhibitor-induced growth
arrest. FEBS Lett. 554:347–350. 2003.
|
|
23
|
Matsuzaki Y, Koyama M, Hitomi T, Kawanaka
M and Sakai T: Indole-3-carbinol activates the cyclin-dependent
kinase inhibitor p15INK4b gene. FEBS Lett. 576:137–140.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Koyama M, Matsuzaki Y, Yogosawa S, Hitomi
T, Kawanaka M and Sakai T: ZD1839 induces p15INK4b and
causes G1 arrest by inhibiting the mitogen-activated protein
kinase/extracellular signal-regulated kinase pathway. Mol Cancer
Ther. 6:1579–1587. 2007.PubMed/NCBI
|
|
25
|
Yamaguchi T, Yoshida T, Kurachi R,
Kakegawa J, Hori Y, Nanayama T, Hayakawa K, Abe H, Takagi K,
Matsuzaki Y, Koyama M, Yogosawa S, Sowa Y, Yamori T, Tajima N and
Sakai T: Identification of JTP-70902, a
p15INK4b-inductive compound, as a novel MEK1/2
inhibitor. Cancer Sci. 98:1809–1816. 2007.PubMed/NCBI
|
|
26
|
Sowa Y, Orita T, Minamikawa S, Nakano K,
Mizuno T, Nomura H and Sakai T: Histone deacetylase inhibitor
activates the WAF1/Cip1 gene promoter through the Sp1 sites.
Biochem Biophys Res Commun. 241:142–150. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Takagaki N, Sowa Y, Oki T, Nakanishi R,
Yogosawa S and Sakai T: Apigenin induces cell cycle arrest and
p21/WAF1 expression in a p53-independent pathway. Int J Oncol.
26:185–189. 2005.PubMed/NCBI
|
|
28
|
Matsui TA, Sowa Y, Murata H, Takagi K,
Nakanishi R, Aoki S, Yoshikawa M, Kobayashi M, Sakabe T, Kubo T and
Sakai T: The plant alkaloid cryptolepine induces
p21WAF1/Cip1 and cell cycle arrest in a human
osteosarcoma cell line. Int J Oncol. 31:915–922. 2007.PubMed/NCBI
|
|
29
|
Esteller M, Corn PG, Baylin SB and Herman
JG: A gene hypermethylation profile of human cancer. Cancer Res.
61:3225–3229. 2001.PubMed/NCBI
|
|
30
|
Krimpenfort P, Ijpenberg A, Song JY, van
der Valk M, Nawijn M, Zevenhoven J and Berns A: p15INK4b
is a critical tumour suppressor in the absence of
p16Ink4a. Nature. 448:943–947. 2007.
|
|
31
|
Abbas T and Dutta A: p21 in cancer:
intricate networks and multiple activities. Nat Rev Cancer.
9:400–414. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
LaBaer J, Garrett MD, Stevenson LF,
Slingerland JM, Sandhu C, Chou HS, Fattaey A and Harlow E: New
functional activities for the p21 family of CDK inhibitors. Genes
Dev. 11:847–862. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Canman CE, Gilmer TM, Coutts SB and Kastan
MB: Growth factor modulation of p53-mediated growth arrest versus
apoptosis. Genes Dev. 9:600–611. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Abukhdeir AM and Park BH: p21 and p27:
roles in carcinogenesis and drug resistance. Expert Rev Mol Med.
10:e192008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Phillips LR, Malspeis L and Supko JG:
Pharmacokinetics of active drug metabolites after oral
administration of perillyl alcohol, an investigational
antineoplastic agent, to the dog. Drug Metab Dispos. 23:676–680.
1995.PubMed/NCBI
|
|
36
|
Ripple GH, Gould MN, Stewart JA, Tutsch
KD, Arzoomanian RZ, Alberti D, Feierabend C, Pomplun M, Wilding G
and Bailey HH: Phase I clinical trial of perillyl alcohol
administered daily. Clin Cancer Res. 4:1159–1164. 1998.PubMed/NCBI
|
|
37
|
Ripple GH, Gould MN, Arzoomanian RZ,
Alberti D, Feierabend C, Simon K, Binger K, Tutsch KD, Pomplun M,
Wahamaki A, Marnocha R, Wilding G and Bailey HH: Phase I clinical
and pharmacokinetic study of perillyl alcohol administered four
times a day. Clin Cancer Res. 6:390–396. 2000.PubMed/NCBI
|
|
38
|
Hudes GR, Szarka CE, Adams A, Ranganathan
S, McCauley RA, Weiner LM, Langer CJ, Litwin S, Yeslow G, Halberr
T, Qian M and Gallo JM: Phase I pharmacokinetic trial of perillyl
alcohol (NSC 641066) in patients with refractory solid
malignancies. Clin Cancer Res. 6:3071–3080. 2000.PubMed/NCBI
|
|
39
|
Sakai T: Molecular cancer epidemiology -
the present status and future possibilities. Jpn J Hygiene.
50:1036–1046. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sowa Y and Sakai T: Butyrate as a model
for ‘Gene-regulating chemoprevention and chemotherapy’. Biofactors.
2:283–287. 2000.
|
